{"disease":{"id":"anemia-in-chronic-kidney-disease","name":"Anemia in chronic kidney disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":14,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"roxadustat","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Evrenzo","generic_name":"ROXADUSTAT","company_name":"Astellas Pharma Europe B.V.","drug_phase":"marketed","molecular_target":"Thyroid hormone receptor beta","drug_class":"","quality_score":35,"revenue":"600","mechanism":""},{"drug_id":"retacrit","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epogen","generic_name":"Epoetin Alfa-Epbx","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating agent (ESA)","quality_score":10,"revenue":"400","mechanism":"Epoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin."},{"drug_id":"epoetin-alfa","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epogen","generic_name":"EPOETIN ALFA","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating Agent","quality_score":63,"revenue":"400","mechanism":"Epogen works by binding to the erythropoietin receptor, triggering a cascade of signals that stimulate the production of red blood cells."},{"drug_id":"epoetin-zeta","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Silapo","generic_name":"EPOETIN ZETA","company_name":"Hospira UK Limited","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"methoxy-polyethylene-glycol-epoetin-beta","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mircera","generic_name":"METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"erythropoietin receptor","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Mircera activates erythropoietin receptors, increasing red cell production in response to hypoxia."},{"drug_id":"epogen","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Epogen","company_name":"Johns Hopkins University","drug_phase":"discontinued","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"procrit","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Procrit","company_name":"University of Louisville","drug_phase":"discontinued","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"erythropoietin","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Erythropoietin","company_name":"Nanjing First Hospital, Nanjing Medical University","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":null},{"drug_id":"epoetin-beta","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neorecormon","generic_name":"EPOETIN BETA","company_name":"Roche Registration Limited","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Neorecormon works by binding to the erythropoietin receptor, mimicking the action of natural erythropoietin to stimulate red blood cell production."},{"drug_id":"mircera","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mircera","company_name":"Samsung Medical Center","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"enarodustat","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enaroy","generic_name":"ENARODUSTAT","company_name":"Japan Tabacco","drug_phase":"marketed","molecular_target":"Egl nine homolog 1","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"neorecormon","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neorecormon","company_name":"Centre Hospitalier Universitaire, Amiens","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"daprodustat","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jesduvroq","generic_name":"DAPRODUSTAT","company_name":"GSK","drug_phase":"marketed","molecular_target":"Egl nine homolog 1","drug_class":"Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Jesduvroq works by activating hypoxia-inducible factor prolyl hydroxylase inhibitors, which increases the production of erythropoietin, a hormone that stimulates red blood cell production."},{"drug_id":"nandrolone-decanoate","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nandrolone Decanoate","generic_name":"NANDROLONE DECANOATE","company_name":"Woodward Specl","drug_phase":"marketed","molecular_target":"Sex hormone-binding globulin","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":14,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07098416","title":"A Real-World Study About Anemia in Chronic Kidney Disease in China（DASHENG）","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Wei Chen","has_results":false},{"nct_id":"NCT03945968","title":"The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.","phase":"","overall_status":"RECRUITING","enrollment_count":16000,"lead_sponsor_name":"Russian Federation of Anesthesiologists and Reanimatologists","has_results":false},{"nct_id":"NCT01652872","title":"Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":756,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT02021318","title":"Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":616,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT01887600","title":"Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":594,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT02950142","title":"Evidence-based Laboratory Test Order Sets in Primary Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":288,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT06016036","title":"SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT01964196","title":"ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT04893187","title":"A Phase 1 Study of SSS17 in Healthy Subjects.","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":76,"lead_sponsor_name":"Shenyang Sunshine Pharmaceutical Co., LTD.","has_results":false},{"nct_id":"NCT04317833","title":"A Study of SSS17 in Healthy Subjects","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":65,"lead_sponsor_name":"Shenyang Sunshine Pharmaceutical Co., LTD.","has_results":false},{"nct_id":"NCT04197778","title":"Food Effect Study of DDO-3055 Tablets in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}